Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Monopar Therapeutics Inc. (MNPR)

1.48   0.02 (1.37%) 09-24 16:16
Open: 1.53 Pre. Close: 1.46
High: 1.54 Low: 1.45
Volume: 5,148 Market Cap: 19(M)
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo EspaƱol de InvestigaciĆ³n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.54 - 1.55 1.55 - 1.56
Low: 1.43 - 1.44 1.44 - 1.45
Close: 1.46 - 1.48 1.48 - 1.49

Technical analysis

as of: 2022-09-23 4:25:57 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.95     One year: 2.16
Support: Support1: 1.39    Support2: 1.15
Resistance: Resistance1: 1.67    Resistance2: 1.85
Pivot: 1.62
Moving Average: MA(5): 1.51     MA(20): 1.66
MA(100): 2.02     MA(250): 2.91
MACD: MACD(12,26): -0.2     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 23     %D(3): 27.8
RSI: RSI(14): 28.7
52-week: High: 5.73  Low: 1.39
Average Vol(K): 3-Month: 9 (K)  10-Days: 10 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MNPR ] has closed above bottom band by 11.7%. Bollinger Bands are 0.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 08 Sep 2022
Monopar Therapeutics Inc. (MNPR) Stock Price Today, Quote & News - Seeking Alpha

Mon, 16 May 2022
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace

Thu, 24 Mar 2022
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments - GlobeNewswire

Tue, 15 Feb 2022
Monopar Announces Clinical and Preclinical Program Updates - GlobeNewswire

Wed, 02 Feb 2022
Sara revs up VP bid with bike caravan - The Manila Times

Wed, 02 Feb 2022
Sara thanks supporters for campaign caravan's success - pna.gov.ph

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 13 (M)
Shares Float 4 (M)
% Held by Insiders 64.9 (%)
% Held by Institutions 1.6 (%)
Shares Short 7 (K)
Shares Short P.Month 7 (K)

Stock Financials

EPS -0.71
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.69
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -27.6
Return on Equity (ttm) -46
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -8 (M)
Levered Free Cash Flow -4 (M)

Stock Valuations

PE Ratio -2.11
PEG Ratio 0
Price to Book value 0.87
Price to Sales 0
Price to Cash Flow -2.38

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.